Newsletter Tool

To view this email as a web page, click here

Today's Rundown

Pfizer, BioNTech snare $1.95B deal with U.S. government for 100M-plus doses of COVID-19 vaccine
Providers press Senate to add $100B in relief funds in next COVID-19 package
Here is how execs from Oscar Health, Intermountain and Cerner say the telehealth boom will change healthcare
In conversation with Vaccitech CEO Enright on pandemic vaccines
Planning ahead: U.S., Canada order 177M more COVID-19 vaccine syringes from BD
Healthcare roundup: Health groups push for greater funding for testing
Biopharma roundup: U.S. shores up syringe supply with BD; Novavax inks incentive awards for phase 2 vaccine trial: report
HCA Healthcare shares jump after beating Q2 expectations despite COVID-19
Biogen's lagging Vumerity, stalled by the pandemic, faces 'critical' stretch ahead, CEO says
IQVIA moves Bruehlman into chief financial exec role as sales fall amid pandemic

Featured Story

Pfizer, BioNTech snare $1.95B deal with U.S. government for 100M-plus doses of COVID-19 vaccine

By Kyle Blankenship

The Trump administration's Warp Speed initiative has placed its biggest bet yet on an accelerated COVID-19 vaccine—and Pfizer and BioNTech are the lucky recipients. The U.S. will pay $1.95 billion for 100 million doses, pending an approval, and has an option on another 500 million after that.

Providers press Senate to add $100B in relief funds in next COVID-19 package

By Robert King

The AMA, AHA and ANA wrote to Senate leadership asking for $100 billion to be included in a new COVID-19 legislative package being hammered out by Congress.

Here is how execs from Oscar Health, Intermountain and Cerner say the telehealth boom will change healthcare

By Heather Landi

There is a general consensus that virtual care is here to stay. What does that mean for the future of healthcare delivery? Industry leaders share their perspectives on the changes that might be coming.

In conversation with Vaccitech CEO Enright on pandemic vaccines

By Ben Adams

Vaccitech is a spinout company from the University of Oxford's Jenner Institute, one of the oldest and most renowned vaccine research centers in the world.

Planning ahead: U.S., Canada order 177M more COVID-19 vaccine syringes from BD

By Conor Hale

Many countries are working to have the necessary medical infrastructure in place before a COVID-19 vaccine is proven effective. And now, as promising data begins to trickle in from a number of drugmakers, the U.S. is nearly quadrupling its orders for needles and syringes made by BD.

Healthcare roundup: Health groups push for greater funding for testing

By Healthcare Staff

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

Biopharma roundup: U.S. shores up syringe supply with BD; Novavax inks incentive awards for phase 2 vaccine trial: report

By Eric Sagonowsky, Angus Liu, Kyle Blankenship, Conor Hale, Fraiser Kansteiner

The CEO of Vaccitech, spun out from Oxford's Jenner Institute, broke down early trial data on the AstraZenca-partnered shot. Novavax will pay its CEO millions once the firm's vaccine candidate enters phase 2. The U.S. tapped BD for 140 million additional injector devices, and the Northeast is leading the charge for virus response.

HCA Healthcare shares jump after beating Q2 expectations despite COVID-19

By Tina Reed

Nashville, Tennessee-based health system giant HCA Healthcare saw its shares jump Wednesday after reporting better-than-expected results in the second quarter.

Biogen's lagging Vumerity, stalled by the pandemic, faces 'critical' stretch ahead, CEO says

By Eric Sagonowsky

Biogen’s Tecfidera follow-up Vumerity hit the market late last year, but eight months into the launch, the new multiple sclerosis drug is yet to meaningfully take off. It's a bad sign for Biogen after a recent patent loss for Tecfidera, and the company's CEO acknowledged the "disappointing" performance. The drug faces an important few months ahead, he added.

IQVIA moves Bruehlman into chief financial exec role as sales fall amid pandemic